Baird Maintains Outperform on bluebird bio, Lowers Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Jack Allen has maintained an Outperform rating on bluebird bio (NASDAQ:BLUE) but has reduced the price target from $10 to $7.
December 12, 2023 | 4:07 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Baird has maintained an Outperform rating on bluebird bio but lowered the price target from $10 to $7, indicating a potential downside compared to the previous target.
The reduction in price target by Baird suggests that they see less upside potential for bluebird bio's stock price in the short term. This could lead to a negative investor sentiment and a potential decrease in the stock price as the new target is lower than the previous one.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100